{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:03:04Z","timestamp":1770746584385,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40256-024-00654-4","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:02:42Z","timestamp":1719226962000},"page":"641-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Efficacy of Tafolecimab in Chinese Patients with Hypercholesterolemia: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7103-9364","authenticated-orcid":false,"given":"Eeshal","family":"Fatima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheer","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikail","family":"Khanzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obaid Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"issue":"3","key":"654_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jama.284.3.311","volume":"284","author":"J Stamler","year":"2000","unstructured":"Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284(3):311\u20138. https:\/\/doi.org\/10.1001\/jama.284.3.311.","journal-title":"JAMA"},{"issue":"25","key":"654_CR2","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"19","key":"654_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehv028.","journal-title":"Eur Heart J"},{"issue":"16","key":"654_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1500858.","journal-title":"N Engl J Med"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2147\/VHRM.S275739","volume":"1","author":"X Jia","year":"2022","unstructured":"Jia X, Al Rifai M, Saeed A, Ballantyne CM, Virani SS. PCSK9 inhibitors in the management of cardiovascular risk: a practical guidance. Vasc Health Risk Manag. 2022;1:555\u201366. https:\/\/doi.org\/10.2147\/VHRM.S275739.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"654_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/2FHEARTVIEWS.HEARTVIEWS_59_19","volume":"20","author":"R Hajar","year":"2019","unstructured":"Hajar R. PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views Off J Gulf Heart Assoc. 2019;20(2):74. https:\/\/doi.org\/10.4103\/2FHEARTVIEWS.HEARTVIEWS_59_19.","journal-title":"Heart Views Off J Gulf Heart Assoc"},{"key":"654_CR7","unstructured":"Pokhrel B, Yuet WC, Levine SN. PCSK9 inhibitors [Internet]. StatPearls\u2014NCBI Bookshelf. 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448100\/. Accessed 11 Feb 2024."},{"issue":"5","key":"654_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18773\/2Faustprescr.2016.060","volume":"39","author":"MM Page","year":"2016","unstructured":"Page MM, Watts GF. PCSK9 inhibitors\u2013mechanisms of action. Aust Prescr. 2016;39(5):164. https:\/\/doi.org\/10.18773\/2Faustprescr.2016.060.","journal-title":"Aust Prescr"},{"issue":"1","key":"654_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/2Fs12916-023-02797-8","volume":"21","author":"M Chai","year":"2023","unstructured":"Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, An P. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77. https:\/\/doi.org\/10.1186\/2Fs12916-023-02797-8.","journal-title":"BMC Med"},{"key":"654_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lanwpc.2023.100907","volume":"1","author":"Y Huo","year":"2023","unstructured":"Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, Qu Y, Zheng G, Li L, Ji Y, Yin G. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023;1:41. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100907.","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"654_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, Lian Q. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4) a randomized, double-blind, placebo-controlled phase 3 trial. JACC Asia. 2023;3(4):636\u201345. https:\/\/doi.org\/10.1016\/j.jacasi.2023.04.011.","journal-title":"JACC Asia"},{"issue":"3","key":"654_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/2Fj.jacasi.2021.09.002","volume":"1","author":"Y Cui","year":"2021","unstructured":"Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, Qian L, Deng H, Li H, Huo Y. A potential long-acting LDL-cholesterol-lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies. JACC Asia. 2021;1(3):411\u20135. https:\/\/doi.org\/10.1016\/2Fj.jacasi.2021.09.002.","journal-title":"JACC Asia"},{"issue":"38","key":"654_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejim.2016.10.009","volume":"1","author":"XX He","year":"2017","unstructured":"He XX, Zhang R, Zuo PY, Liu YW, Zha XN, Shan SS, Liu CY. The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. Eur J Intern Med. 2017;1(38):52\u201360. https:\/\/doi.org\/10.1016\/j.ejim.2016.10.009.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"654_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.054.","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_2","key":"654_CR15","doi-asserted-by":"publisher","first-page":"ehaa946","DOI":"10.1093\/ehjci\/ehaa946.3327","volume":"41","author":"Y Cui","year":"2020","unstructured":"Cui Y, Huo Y, Li X, Yang G, Huang Z, Zhao X, Qi L, Deng H, Zheng S, An P, Sun X. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. Eur Heart J. 2020;41(Supplement_2):ehaa946\u20133327. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3327.","journal-title":"Eur Heart J"},{"issue":"88","key":"654_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"1","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;1(88): 105906. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"Int J Surg"},{"key":"654_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"7650","key":"654_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"7651","key":"654_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336(7651):995\u20138. https:\/\/doi.org\/10.1136\/bmj.39490.551019.BE.","journal-title":"BMJ"},{"issue":"1","key":"654_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-10429-0","volume":"21","author":"M Amini","year":"2021","unstructured":"Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):1\u20132. https:\/\/doi.org\/10.1186\/s12889-021-10429-0.","journal-title":"BMC Public Health"},{"issue":"1","key":"654_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41525-021-00190-z","volume":"6","author":"S Saadatagah","year":"2021","unstructured":"Saadatagah S, Jose M, Dikilitas O, Alhalabi L, Miller AA, Fan X, Olson JE, Kochan DC, Safarova M, Kullo IJ. Genetic basis of hypercholesterolemia in adults. NPJ Genom Med. 2021;6(1):28. https:\/\/doi.org\/10.1038\/s41525-021-00190-z.","journal-title":"NPJ Genom Med"},{"issue":"47","key":"654_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.15585\/mmwr.mm6447a1","volume":"64","author":"C Mercado","year":"2015","unstructured":"Mercado C, DeSimone AK, Odom E, Gillespie C, Ayala C, Loustalot F. Prevalence of cholesterol treatment eligibility and medication use among adults\u2014United States, 2005\u20132012. Morb Mortal Wkly Rep. 2015;64(47):1305\u201311.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"11","key":"654_CR23","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.3390\/ijms19113426","volume":"19","author":"A Benito-Vicente","year":"2018","unstructured":"Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 2018;19(11):3426. https:\/\/doi.org\/10.3390\/ijms19113426.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"654_CR24","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.057.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"654_CR25","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","volume":"68","author":"JG Robinson","year":"2016","unstructured":"Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68(22):2412\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.928.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"654_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pharmacy6010010","volume":"6","author":"D Zodda","year":"2018","unstructured":"Zodda D, Giammona R, Schifilliti S. Treatment strategy for dyslipidemia in cardiovascular disease prevention: focus on old and new drugs. Pharmacy. 2018;6(1):10. https:\/\/doi.org\/10.3390\/pharmacy6010010.","journal-title":"Pharmacy"},{"issue":"1","key":"654_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","volume":"71","author":"M Ogura","year":"2018","unstructured":"Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1\u20137. https:\/\/doi.org\/10.1016\/j.jjcc.2017.07.002.","journal-title":"J Cardiol"},{"issue":"16","key":"654_CR28","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1501031.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00654-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00654-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00654-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T16:09:56Z","timestamp":1724515796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00654-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00654-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"12 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eeshal Fatima, Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Obaid Ur Rehman, and Faryal Altaf declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"EF: Writing\u2014original draft, conceptualization, data analysis, methodology. ZQ: Writing\u2014original draft, conceptualization. MK: Writing\u2014original draft. AS: Writing\u2014original draft. OUR: Writing\u2014original draft. FA: Writing\u2014review and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}